Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $745.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective lifted by research analysts at Wells Fargo & Company from $700.00 to $745.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price target indicates a potential upside of 2.43% from the company’s previous close.

A number of other equities research analysts also recently weighed in on the company. Bank of America raised their price target on Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the stock an “underperform” rating in a research note on Wednesday, October 29th. Sanford C. Bernstein lifted their target price on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a research note on Wednesday, August 27th. Hsbc Global Res upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 24th. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday, September 2nd. Finally, UBS Group increased their target price on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $779.41.

Regeneron Pharmaceuticals Stock Up 5.0%

REGN stock traded up $34.77 during midday trading on Wednesday, reaching $727.35. The company had a trading volume of 674,084 shares, compared to its average volume of 1,097,241. The company has a 50 day moving average of $656.15 and a two-hundred day moving average of $589.72. The company has a market capitalization of $76.44 billion, a P/E ratio of 17.42, a PEG ratio of 2.01 and a beta of 0.37. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $790.98. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. During the same period in the prior year, the business posted $12.46 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up .9% compared to the same quarter last year. On average, equities research analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the sale, the director directly owned 2,352 shares in the company, valued at $1,538,843.04. This trade represents a 73.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Jason Pitofsky sold 431 shares of the stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Marino Stram & Associates LLC raised its stake in shares of Regeneron Pharmaceuticals by 5.3% in the 2nd quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 20 shares in the last quarter. CoreCap Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 9.2% in the 3rd quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock worth $134,000 after buying an additional 20 shares in the last quarter. Activest Wealth Management lifted its position in shares of Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 21 shares during the period. Strait & Sound Wealth Management LLC grew its position in Regeneron Pharmaceuticals by 3.5% in the third quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock valued at $353,000 after acquiring an additional 21 shares during the period. Finally, Parkside Financial Bank & Trust grew its holdings in shares of Regeneron Pharmaceuticals by 14.8% in the 3rd quarter. Parkside Financial Bank & Trust now owns 163 shares of the biopharmaceutical company’s stock worth $92,000 after purchasing an additional 21 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.